20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
Public ClinicalTrials.gov record NCT01568216. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms"
Study identification
- NCT ID
- NCT01568216
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 121 participants
Conditions and interventions
Conditions
Interventions
- AMG 747 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2012
- Primary completion
- May 31, 2013
- Completion
- May 31, 2013
- Last update posted
- Jul 29, 2015
2012 – 2013
United States locations
- U.S. sites
- 18
- U.S. states
- 10
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anaheim | California | 92804 | — |
| Research Site | Cerritos | California | 90703 | — |
| Research Site | Culver City | California | 90230 | — |
| Research Site | Garden Grove | California | 92845 | — |
| Research Site | Los Angeles | California | 90073 | — |
| Research Site | Norwalk | California | 90650 | — |
| Research Site | San Bernardino | California | 92408 | — |
| Research Site | Torrance | California | 90502 | — |
| Research Site | Washington D.C. | District of Columbia | 20016 | — |
| Research Site | North Miami | Florida | 33161 | — |
| Research Site | Atlanta | Georgia | 30308 | — |
| Research Site | Chicago | Illinois | 60640 | — |
| Research Site | Marlton | New Jersey | 08053 | — |
| Research Site | Glen Oaks | New York | 11004 | — |
| Research Site | Rochester | New York | 14618 | — |
| Research Site | Raleigh | North Carolina | 27603 | — |
| Research Site | Dayton | Ohio | 45417 | — |
| Research Site | Houston | Texas | 77008 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01568216, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2015 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01568216 live on ClinicalTrials.gov.